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Inhibition of the translesion synthesis polymerase REV1
exploits replication gaps as a cancer vulnerability
Sumeet Nayak1, Jennifer A. Calvo1, Ke Cong1, Min Peng1, Emily Berthiaume1, Jessica Jackson2,
Angela M. Zaino3, Alessandro Vindigni2, M. Kyle Hadden3, Sharon B. Cantor1*

INTRODUCTION

The replication stress response is activated in response to DNA lesions or intrinsic replication fork barriers and is critical to ensure
the accurate transmission of genetic material to daughter cells. In
response to sustained replication stress, replication forks slow and
remodel into reversed fork structures. This local fork response is
thought to confer a signal to arrest DNA replication throughout the
cell (1, 2). Cells either undergo replication stress–associated senescence or engage in DNA repair or other transactions that help restart stalled DNA replication forks. The replication stress response
is also induced by oncogenes, making it a critical barrier to cancer
(3–8). However, the oncogene-inducing lesion that limits fitness and
is eventually overcome in cancer remains unknown. Confounding
this understanding, oncogenes have been shown to both accelerate
and slow replication (9–11). These disparate findings could reflect
distinct experimental systems or kinetics of analysis (3, 5, 7). Thus,
it will be critical to further address how cellular replication responds
in the immediate aftermath of replication stress induced by drugs or
oncogene expression.
A pathway known for tolerating DNA damage that interferes
with replicative polymerases is translesion synthesis (TLS) (12).
TLS polymerases are recruited to bypass replication blocking lesions
when replicative polymerases are not functional or physically blocked
(13). TLS polymerases have been implicated in bypassing DNA damage
induced by chemotherapies such as cisplatin, providing a reason for
TLS inhibition in cancer therapy (14–16). While most appreciated
in bypass of DNA adducts, emerging evidence reveals that TLS
polymerases are activated in the absence of DNA damage and are
required for replication of DNA structures enhanced by DNA replication stress such as G-quadruplexes (G4s), which limit replication
progression and promote single-stranded DNA (ssDNA) gap formation (12, 17–19). Conceivably, ssDNA gaps underlie the mecha1
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nism of action of genotoxic therapies, and gap suppression (GS) is
the key factor that confers resistance (20, 21).
Here, we propose that the primary function of TLS polymerases
is GS, to confer chemoresistance and overcome oncogene-induced
replication stress (8). Specifically, we show that TLS polymerases
maintain continuous replication to limit ssDNA gaps induced by
replication stress, oncogenes, or chemotherapy. Moreover, we identify several cancer cell lines that are dependent on TLS polymerases
for replication and fitness, suggesting that a TLS polymerase rewiring
is essential for cancer initiation and/or evolution. A small-molecule
inhibitor targeting the C-terminal domain of the TLS factor REV1
(REV1-CT), which inhibits its interaction with other TLS polymerases,
not only disrupts DNA replication and cancer cell fitness but also
synergizes with gap-inducing therapies. This work implicates that GS
is the fundamental mechanism of overcoming the anticancer barrier
and that TLS inhibition is critical for therapy response.
RESULTS

TLS polymerases limit replication fork slowing during stress
To test the hypothesis that TLS polymerases avoid the replication
stress response (Fig. 1A), we sought to study replication fork dynamics using DNA fiber spreading analysis in cells with enhanced
TLS polymerase activity (hereafter called pro-TLS cells). TLS polymerases are favored when the DNA helicase FANCJ is disrupted
for either its DNA damage–induced acetylation or BRCA1 binding
(22, 23). Here, we used the FANCJ-BRCA1 interaction defective
mutant, FANCJS990A, that promotes TLS polymerase focal accumulation and dependence on TLS factors for chemotherapy resistance
(23). We complemented FANCJ knockout (K/O) U2OS osteosarcoma
cancer cells and FANCJ-null FA-J patient immortalized fibroblast
cells with FANCJS990A (pro-TLS), FANCJWT (control), or vector (V).
As expected, we found that both FANCJWT and FANCJS990A elevated
mitomycin C (MMC) resistance as compared with vector (Fig. 1B
and fig. S1, A and B) (23, 24). To track the actively replicating fork,
cells were labeled with sequential pulses of 5-iodo-2′-deoxyuridine
(IdU) and 5-chloro-2′-deoxyuridine (CldU), and the DNA tract
lengths were measured. DNA fiber spreading analysis revealed that
under unchallenged conditions, vector-, control-, or pro-TLS U2OS– or
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Downloaded from http://advances.sciencemag.org/ on September 2, 2020

The replication stress response, which serves as an anticancer barrier, is activated not only by DNA damage and
replication obstacles but also oncogenes, thus obscuring how cancer evolves. Here, we identify that oncogene
expression, similar to other replication stress–inducing agents, induces single-stranded DNA (ssDNA) gaps that
reduce cell fitness. DNA fiber analysis and electron microscopy reveal that activation of translesion synthesis (TLS)
polymerases restricts replication fork slowing, reversal, and fork degradation without inducing replication gaps
despite the continuation of replication during stress. Consistent with gap suppression (GS) being fundamental to
cancer, we demonstrate that a small-molecule inhibitor targeting the TLS factor REV1 not only disrupts DNA replication and cancer cell fitness but also synergizes with gap-inducing therapies such as inhibitors of ATR or Wee1. Our
work illuminates that GS during replication is critical for cancer cell fitness and therefore a targetable vulnerability.
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Fig. 1. TLS polymerases limit replication fork slowing, reversal, degradation, and gap induction. (A) Model to test whether TLS promotes unrestrained replication
without gaps upon stress. (B) Western blot analysis with the indicated antibodies (Abs) of whole-cell extract (WCE) from U2OS control and FANCJ K/O cells complemented
with vector (V), wild type (FANCJWT), and the FANCJ-BRCA1 binding–deficient mutant (FANCJS990A). (C and D) Schematic and quantification of CldU tract length under
unchallenged condition or following coincubation with 0.5 mM HU or 2 J/m2 UV or 20 M TLSi or after S1 nuclease treatment. (E) Schematic representation of reversed
fork structure and quantification following a 2-hour HU treatment. Number of reversed forks analyzed; untreated, ~70 (V), 94 (WT), and 84 (S990A); HU treated, ~167 (V),
130 (WT), and 176 (S990A). (F) Schematic and quantification of CldU/IdU ratio following 4 mM HU. (G) Western blot analysis with the indicated Abs of WCE from PEO1 cells
expressing V5 tagged—(V), (FANCJWT), and (FANCJS990A). Schematic and quantification of CldU/IdU ratio following HU treatment. Each dot represents 1 fiber and at least
200 fibers quantified from two independent experiments. Bars represent the means ± SD. Statistical analysis was performed according to two-tailed Mann-Whitney test.
All P values are described in the “Statistical methods.”

FA-J–complemented cell lines had similar tract lengths, indicating
that TLS polymerase induction did not affect normal replication
progression (Fig. 1C and fig. S1C). However, when CldU labeling was
Nayak et al., Sci. Adv. 2020; 6 : eaaz7808
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coincident with 0.5 mM hydroxyurea (HU), a dose that does not completely deplete nucleotide pools but activates replication stress (25),
control cells had an expected reduction in tract lengths as compared
2 of 12
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TLS polymerases promote replication fork progression
during stress without ssDNA gap induction
Failure to slow replication during stress is associated with fork degradation, genomic instability, and low fitness (1, 24, 30). We reasoned that TLS polymerase–dependent replication during stress
could avoid this outcome by suppressing ssDNA gaps, a replication
stress–associated lesion (24, 31). To test this hypothesis, DNA fiber
assays were performed in the presence or absence of S1 nuclease
treatment. S1 nuclease degrades DNA fibers with ssDNA gaps that
occur within the labeled replication tracts, not easily observable in
the standard DNA fiber assay (32). We observed that pro-TLS cells
generated significantly longer tracts that were maintained even after
S1 nuclease treatment (Fig. 1D and fig. S1F). These findings further
indicate that the failure to slow replication during stress is not associated with repriming or new origin firing. Moreover, these findings
indicate that in response to stress, TLS polymerases not only disrupt
fork slowing, but replication continues without generating ssDNA
gaps. Further validating TLS polymerases as the mechanism of fork
elongation during stress, replication tract lengthening does not
occur during stress in cells expressing the TLS inactivating mutant FANCJS990A+K52R (pro-TLS + helicase dead) as found for the
FANCJK52R (helicase dead) mutant (fig. S1F) (23, 33). Notably, in
response to the UV or HU (1 hour) fork slowing assay, replication
tracts in FANCJ-deficient cells are longer than WT, and the longer
Nayak et al., Sci. Adv. 2020; 6 : eaaz7808
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HU tracts shorten with S1 consistent with ssDNA gaps due to either
repriming and/or new origin firing (Fig. 1D and fig. S1F). However,
in the HU (2 hours) fork slowing assay, replication tracts in FANCJ-
deficient cells and WT are similar (Fig. 1C), suggesting that longer-
gapped replication tracts in the FANCJ-deficient cells eventually
undergo fork degradation.
TLS polymerases avoid fork reversal and degradation
We predicted that continued replication during stress would limit
replication fork reversal. To directly visualize and investigate the
frequency of reversed fork intermediates in cells with or without
TLS induction, we analyzed the fine replication fork architecture by
using psoralen cross-linking coupled to electron microscopy (EM).
Following treatment with 4 mM HU to ensure nucleotide depletion
and replication fork stalling, we found a significant accumulation of
the reversed fork structures in the control cells (~28% reversed forks),
whereas pro-TLS cells exhibited significantly lower frequency (~11%)
of fork reversal events (Fig. 1E). Collectively, these results suggest
that TLS restricts fork reversal.
We reasoned that a reduction in fork reversal by TLS would in
turn prevent fork degradation and enhance fork protection. To access fork degradation, we analyzed the ratio of CldU to IdU tract
lengths following sequential pulses with IdU and CldU followed by
HU treatment (Fig. 1F) (34). Compared with control, the pro-TLS
cells had a modestly enhanced CldU-to-IdU tract length ratio, consistent with less fork degradation upon stress (Fig. 1F and fig. S1G).
Moreover, pro-TLS cells also maintained fork integrity following a
prolonged period of replication stress. In addition, in fork degradation–
prone BRCA2-deficient PEO1 ovarian cancer cells (34–38), ectopic
expression of the pro-TLS FANCJ mutant not only promoted unrestrained replication and enhanced fork protection but also conferred cisplatin resistance as compared with control (Fig. 1G and
fig. S1H). Together, these findings indicate that TLS provides fork
protection through suppression of fork remodeling similar to the
loss of fork remodelers (36, 38, 39).
TLS polymerases disrupt the global replication stress
response without ssDNA induction
During stress, fork slowing and remodeling promote the global
arrest of DNA replication (Fig. 1A) (2). Thus, TLS polymerases
counteracting fork slowing in response to stress could also limit the
global arrest of DNA replication. To test this idea, an asynchronous
population of the control or the pro-TLS U2OS cell lines was either
left untreated or treated with varying doses of HU while also being
labeled with 5-ethynyl-2′-deoxyuridine (EdU) to track active replication. Replication was quantified by scoring the number of
EdU-positive cells. Under unperturbed conditions, the number of EdU-
positive cells was similar between the control and pro-TLS U2OS
cells, further suggesting that TLS does not impact the global replication in unchallenged conditions (Fig. 2A). However, upon HU
treatment, we observed that the number of EdU-positive cells was
significantly reduced in the control U2OS cells, mimicking the replication fork slowing as studied in the DNA fiber assay (Fig. 2A).
In contrast, the pro-TLS U2OS cells continued to incorporate EdU
not only in low-dose HU but also following UV treatment (fig.
S2C), further validating that TLS polymerases promote replication
during stress.
Similar to our findings with TLS polymerase activity, inhibition of
the checkpoint kinase ATR enables replication during stress (Fig. 2A
3 of 12
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with untreated control, suggesting replication fork slowing during
stress (Fig. 1C and fig. S1D). Similarly, following treatment with ultraviolet (UV) radiation, control cells had a significant shorter tract
length correlative of replication fork slowing (Fig. 1C and fig. S1D).
Notably, the DNA tracts in the pro-TLS U2OS or FA-J cells failed to
fully shorten both during HU and after UV and were significantly
longer than the control (Fig. 1C and fig. S1D), indicating changes in
replication fork progression were neither replication stress nor cell
type specific. Further verifying that TLS polymerases contribute to
the unrestrained replication during stress, tracts fully shortened
when the pro-TLS cells were treated with the TLS inhibitor (TLSi)
that targets the C-terminal domain of REV1 (REV1-CT) and prevents protein-protein interactions (PPIs) between this domain and
the REV1 interacting regions (RIRs) present in multiple other TLS
polymerases, including pol, pol, pol, and pol. Disruption of the
REV1 scaffolding function effectively inhibits the function of these
TLS polymerases and disrupts the TLS pathway in a manner specific
to REV1 (Fig. 1C) (26, 27). In contrast, the TLSi alone did not alter
the length of DNA tracts in unchallenged conditions (fig. S1C).
The longer tracts and the failure to slow replication in the pro-TLS
cells could stem from a more rapid restart of stalled forks, repriming
and/or the firing of new origins upon stress. To address this question, we labeled cells with IdU, arrested replication with high-dose
HU (4 mM), and following release from HU, labeled with CldU. Dual-
labeled tracts were greatly diminished in the vector FA-J cells, and
new origins were aberrantly activated (fig. S1E), corroborating the
role of FANCJ in replication restart and regulating new origin firing
(28, 29). In contrast, FA-J cells complemented with either wild type
(WT) or S990A had comparable levels of dual-labeled replication
tracts consistent with control and pro-TLS cells, promoting replication restart following fork arrest (fig. S1E). Together, these findings
suggest that TLS polymerases limit fork slowing, but upon a full
replication arrest, TLS polymerases do not alter replication restart
or dormant origin firing.
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Fig. 2. TLS polymerases promote global replication during stress and suppress ssDNA gaps. (A) Schematic, representative images, and quantification of EdU- and
ssDNA-positive cells. For EdU assay, cells were labeled with EdU alone either for 30 min or for 2 hours with varying doses of HU −/+ 5 M ATRi. For ssDNA detection, cells
were first labeled with CldU for 48 hours followed by a 2-hour HU treatment. Staining for EdU was performed by ClickiT chemistry, and for ssDNA using CldU-specific Ab
under nondenaturing conditions. Percent EdU- and ssDNA-positive cells were quantified from over 300 cells counted from multiple fields. (B) Schematic, representative
images (63×), and quantification of EdU- and ssDNA-positive cells following initial labeling with CldU for 48 hours followed by EdU treatment with or without 0.5 mM
HU −/+ 20 M TLSi. (C) Western blot analysis with the indicated Abs of WCE from U2OS cells expressing shRNA against NSC or p21. (D and E) Schematic and quantification
of EdU- and ssDNA-positive cells following initial labeling with CldU for 48 hours followed by EdU treatment with or without 0.5 mM HU −/+ 20 M TLSi. Bars represent
the means ± SD. Statistical analysis was performed according to two-tailed Mann-Whitney test. All P values are described in the “Statistical methods.”

and fig. S2G) (2). Given that ATR inhibition is toxic to cells (40), we
considered that a key difference between TLS activation and ATR
inhibition was ssDNA gap induction. To test whether replication
during stress differed by ssDNA gap induction, we performed nondenaturing immunofluorescence following incorporation of CldU
to visualize ssDNA regions that are positive for anti-CldU staining.
Nayak et al., Sci. Adv. 2020; 6 : eaaz7808

10 June 2020

In the presence of HU, we observed that the ATR inhibitor (ATRi)
leads to widespread global ssDNA gaps, whereas by comparison to
control, the pro-TLS cells appeared resistant to gap formation
(Fig. 2A and fig. S2G). Collectively, these findings indicate that TLS,
unlike ATR inhibition, promotes replication during stress without
genome wide ssDNA gap induction.
4 of 12

SCIENCE ADVANCES | RESEARCH ARTICLE

Oncogene expression induces ssDNA gaps and reduces
cell fitness
Oncogene activation is associated with replication stress that serves
as a barrier to cancer (3–9, 43). Given our findings, we sought to test
the hypothesis that oncogene-induced stress can be offset by TLS.
To test this hypothesis, we generated cells stably infected with either
empty vector or CCNE1 vector that encodes the oncogene cyclin
E1 in a doxycycline inducible manner (DOX-ON system) (Fig. 3A).
As previously reported, we observed that cyclin E1 expression did
not alter EdU incorporation (Fig. 3B and fig. S3A) (10, 11, 44).
However, there was a significant induction of genome-wide ssDNA,
as well as loss of clonogenic capacity, both of which were suppressed
by TLS polymerase activation as achieved by FANCJS990A mutant
(Fig. 3, B and C, and fig. S3A). Similar findings were observed in
another well-established U2OS cyclin E1 inducible system (TET-OFF
system) (44). Upon cyclin E1 overexpression (OE), as compared with
the normal ectopic levels (NE), EdU incorporation was unhindered,
but ssDNA was induced and clonogenic survival was reduced unless counteracted by TLS achieved by p21 depletion (Fig. 3, D to F,
and fig. S3C). Furthermore, coincubation with TLSi restored cyclin
E1–induced ssDNA gaps and reduced the clonogenic capacity of the
pro-TLS cells, but had no effect on colonies without any oncogene
induction (Fig. 3, C and F, and fig. S3B). Collectively, these findings
indicate that TLS polymerases buffer oncogene-induced stress to
facilitate continuous replication without ssDNA gap induction and
promote survival.
Cancer cells show TLS polymerase dependence
If TLS polymerases overcome the loss of fitness due to oncogene
expression, then cancer evolution could favor TLS polymerase activation. To identify a possible pro-TLS rewiring in cancer, we tested
the ability of distinct cancer cell types to replicate during stress. We
found that replication robustly continued in the breast cancer cell
line MCF7, the endometrial cancer cell line HeLa, the colon cancer
cell line HCT15, the lung cancer cell lines A549 and NCI-H522, and
Nayak et al., Sci. Adv. 2020; 6 : eaaz7808
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the leukemia cell line MOLT-4 following HU treatment (Fig. 4A and
fig. S4, A and B). Moreover, the TLSi curtailed replication during
stress and induced ssDNA gaps in these cell lines (Fig. 4A and fig. S4B).
Notably, MCF7 cells also showed a flattened morphology suggestive
of senescence (Fig. 4A). HeLa cells halted replication and induced
ssDNA even in the absence of HU (Fig. 4A), consistent with a proTLS phenotype even in unchallenged conditions. In contrast, similar to U2OS cells, the immortalized retinal pigment epithelial (RPE)
cell line ceased to replicate in low-dose HU (fig. S4A).
Consistent with a TLS polymerase rewiring, cancer cell lines with
TLS polymerase–dependent replication lost clonogenic capacity upon
treatment with the TLSi (Fig. 4B), whereas the TLSi did not affect
the colony-forming capacity of cells not dependent on TLS polymerases, such as RPE, U2OS, and the human mammary epithelial
cell line HMEC (Fig. 4B). Moreover, early passage ovarian cancer
ascites cells from two different patients were also highly sensitive to
the TLSi treatment (Fig. 4B). In addition, TLS polymerase–dependent
Hela cancer cells showed dependence on the TLS factor FANCJ for
replication and cellular fitness. Namely, FANCJ K/O in HeLa cells
exhibited significantly reduced DNA replication and impaired clonogenic capacity (fig. S5, A and B). As compared with the control
HeLa cells, p21 levels were also observed to be elevated in the FANCJ
K/O HeLa cells (fig. S5A), consistent with FANCJ promoting TLS
in part through p21 suppression. p21 depletion in the FANCJ K/O
HeLa cells improved replication, fitness, and suppressed ssDNA gaps,
unless REV1 was inhibited (fig. S5, A, C, and D). Together, these
findings reveal that distinct cancer cell lines rely on TLS polymerases
for continuous replication and fitness, indicating replication gaps as
a cancer vulnerability.
Gap-inducing therapies are also evaded by TLS polymerases
Currently, there is a major clinical effort to treat cancer by induction of replication stress through inhibition of ATR or the mitotic
checkpoint kinase Wee1 (45). Given that these drugs induce replication gaps (Fig. 2A) (8, 40, 46), we considered that if gaps were the
sensitizing lesion, then activated TLS polymerases could also interfere with their effectiveness. Compared with the non-TLS cells, proTLS cells conferred greater clonogenic survival following treatment
with either the ATRi or the Wee1 inhibitor (Wee1i) (Fig. 5, A and B,
and fig. S6, A to D). Similarly, the pro-TLS cancer cell line HCT15
showed resistance to both ATRi and Wee1i (Fig. 5, A and B, and fig.
S6, A to D) (45). However, when coincubated with the TLSi, the pro-
TLS U2OS cells, with either FANCJS990A or p21 depletion, or the
HCT15 cancer cell lines were resensitized, suggesting a more potent
therapeutic response when TLSi is used in combination with ATRi
or Wee1i (Fig. 5, A and B, and fig. S6, A to D). Collectively, these
findings demonstrate that TLS polymerases overcome replication
stress from oncogene expression that explains the prevalence of cancer
cells rewired to depend on TLS polymerases for replication and fitness.
This TLS polymerase rewiring mitigates the effectiveness of drugs
such as ATRi and Wee1i that induces gaps, suggesting the greater
clinical potential of targeting TLS factors as a cancer therapy (Fig. 5C).
DISCUSSION

It has been a long-standing mystery how cancer cells ultimately overcome the replication stress response initiated by oncogenes. It has
also been a challenge to understand the variation in the response of
cancer cells to chemotherapy or different drugs being clinically tested
5 of 12
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To verify that unrestrained replication without ssDNA gaps is a
distinct feature of TLS polymerases and not limited to a pro-TLS
phenotype driven by FANCJ, we depleted the negative regulator of
TLS, p21 (41), in the parental U2OS cell line. To confirm TLS polymerase induction, which is associated with TLS polymerase foci
formation (13, 42), cells were transfected with either enhanced green
fluorescent protein (eGFP)–pol or eGFP-REV1, and foci formation was evaluated in untreated cells or following either UV or MMC
treatment. In response to either stress, we confirmed that pol and
Rev1 foci formation were enriched not only in the pro-TLS U2OS
FANCJS990A cells (23) but also in the p21-depleted cells (fig. S2, A
and B). Furthermore, depletion of p21 led to continuous “ungapped”
replication during HU treatment as compared with the control (Fig. 2,
C and D, and fig. S2D). In either pro-TLS system, FANCJS990A, or
p21 depletion, treatment with TLSi disrupted EdU incorporation
and induced ssDNA gaps (Fig. 2, B and E, and fig. S2E). Notably, in
the pro-TLS cells under unchallenged conditions or in control cells,
the TLSi alone did not interfere with EdU incorporation nor induce
ssDNA gaps (Fig. 2B and fig. S2F), suggesting that the addition of
stress was a prerequisite to induce TLS-dependent replication. Collectively, these findings indicate that TLS polymerases are a robust
mechanism for continuation of replication during stress without
ssDNA gap formation.

SCIENCE ADVANCES | RESEARCH ARTICLE
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Fig. 3. TLS polymerases overcome oncogene-induced stress response and promotes cell fitness. (A) Western blot analysis with the indicated Abs of WCE from U2OS
FANCJWT or FANCJS990A cells with pInducer vector(V) or CCNE1(cyclin E1). Cyclin E1 expression induced with doxycycline (DOX) (1 g/ml) for 24 hours. (B) Schematic and
quantification of EdU- and ssDNA-positive cells. EdU and ssDNA staining were performed as described in Fig. 2. (C) Representative images and quantification of colony
formation following indicated treatments. (D) Western blot analysis with the indicated Abs of WCE from U2OS cyclin E1 inducible cell line expressing shRNA against NSC
or p21. NE, normal level of cyclin E1 (Tet ON); OE, cyclin E1 overexpression (Tet OFF). Arrow indicates cyclin E1 overexpression. (E) Schematic and quantification of
EdU- and ssDNA-positive cells. (F) Representative images and quantification of the colony formation in NSC- versus p21-depleted U2OS cyclin E1 NE or OE cells following
indicated treatments. Experiments were performed in biological triplicate. Bars represent the means ± SD. Statistical analysis was performed according to two-tailed
Mann-Whitney test. All P values are described in the “Statistical methods.”

that inhibit checkpoint kinases, such as ATR or Wee1 (46). On the
basis of our work, we propose that rewired replication that favors TLS
polymerases is an essential adaptation to blunt oncogene-induced
replication stress that otherwise rapidly induces ssDNA gaps and
limits cell fitness. The pro-TLS rewiring also counteracts therapies
that we and others demonstrate induce gaps such ATR or Wee1 inNayak et al., Sci. Adv. 2020; 6 : eaaz7808

10 June 2020

hibitors (Fig. 5C) (8, 40, 46–49). Critically, a small-molecule inhibitor targeting the TLS factor, REV1 (27, 50), not only effectively
disrupts TLS polymerase–dependent DNA replication and cancer
cell fitness but also synergizes with gap-inducing therapies. Collectively, we propose a new model for TLS polymerases in cancer and
therapy response, distinct from lesion bypass to a mechanism of GS.
6 of 12
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Fig. 4. TLS polymerases subvert the replication stress response to promote cancer fitness. (A) Schematic, representative images, and quantification of EdU- and
ssDNA-positive cells following initial labeling with CldU for 48 hours followed by treatment with either EdU alone for 30 min or for 2 hours with or without 0.5 mM HU −/+
20 M TLSi. EdU and ssDNA staining was performed as described in Fig. 2. (B) Representative images and quantification of the colony formation with and without the
continuous presence of 20 M TLSi across the different cell lines. Experiments were performed in biological triplicate. Bars represent the means ± SD. Statistical analysis
was performed according to two-tailed Mann-Whitney test. All P values are described in the “Statistical methods.”

Mechanistically, we uncover that during replication stress, TLS
polymerases curtail the slowing and remodeling of replication forks
and the global replication arrest response while also suppressing
ssDNA gaps. GS may be critical for cell fitness as gaps that persist
are toxic and drive apoptosis (46, 51). Correspondingly, TLS factors
not only tolerate oncogenic stress but are also elevated in cancer to
alleviate replication stress (8, 12, 52, 53). Notably, despite being a
tumor suppressor, FANCJ is overexpressed in many cancers (54–56).
Excess FANCJ could propel TLS because there is insufficient
BRCA1 binding and/or acetylation to limit its TLS activity (22, 23).
Nayak et al., Sci. Adv. 2020; 6 : eaaz7808
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The pro-TLS FANCJ could disrupt secondary DNA fork structures,
fork remodeling factors, or nucleases to limit replication fork
“jumping” that leads to gap formation. FANCJ could also promote
TLS polymerases by stabilizing G-quadruplex secondary structures
that are platforms for REV1 mobilization (57). TLS polymerases are
also likely further licensed because FANCJ suppresses p21, a negative regulator of TLS (41). Similar to FANCJ, other Fanconi anemia
(FA) genes modulate TLS, which could be fundamental to preventing FA.
Our study challenges the model that replication fork slowing and
reversal is a unifying response to genotoxic stress (31), but rather
7 of 12
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Fig. 5. TLS polymerases as a gap suppression mechanism in cancer that can be resensitized by using the TLSi. (A and B) Representative images and quantification
of colony formation after dose-dependent treatment with ATRi (M) and WEE1i (nM) alone or in combination with 20 M TLSi across the different cell lines. (C) Model
summarizing that TLS polymerases are a replication stress avoidance mechanism in cancer. Experiments were performed in biological triplicate. Bars represent the
means ± SD. Statistical analysis was performed according to two-tailed Mann-Whitney test. All P values are described in the “Statistical methods.”

indicates that the response varies depending on the type of genotoxic
agent, kinetics of analysis, and cellular context. For example, U2OS,
RPE, and HMEC cells rapidly arrest replication in response to lowdose HU, whereas MCF7 and HeLa cells continue to replicate. However, U2OS cells similar to other cancer cells continue to replicate in
the immediate aftermath of oncogene expression or treatment with
inhibitors ATR or Wee1 as also found for PARPi (58). While we
envision that the relative toxicity of this continued replication relates
to the abundance of replication gaps that are counteracted by TLS
polymerases, we cannot exclude that there are other toxic DNA structures that interfere with the completion of DNA replication and, thus,
Nayak et al., Sci. Adv. 2020; 6 : eaaz7808
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reduce cell fitness. A key decision point to slow or continue replication during stress is regulated by proliferating cell nuclear antigen
(PCNA). PCNA monoubiquitylation promotes TLS, whereas PCNA
polyubiquitylation provides a nexus for fork remodelers that are
essential for slowing and the reversal of replication forks during
stress (39). As such, loss of fork remodelers, similar to loss of PCNA
ubiquitination, reduces cell fitness and ssDNA gaps accumulate
(24, 59). ATRi also disrupts fork reversal, and gaps develop (2). These
findings suggest that a failure to slow and remodel replication forks
into reversed fork structures is not a productive means for tumorigenesis, at least when replication ssDNA gaps form. Correspondingly,
8 of 12
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Human subjects
Malignant ovarian cancer cells were recovered from ascitic fluids from
patients with ovarian cancer by the University of Massachusetts
Medical School (UMMS) Biorepository and Tissue Bank. Patient consent
was obtained prior to specimen collection under a UMMS Institutional Review Board (IRB)–approved protocol (H4721). Malignant
ovarian cancer cells were recovered from ascitic fluids by centrifugation at 200g and cryopreserved in RPMI media supplemented with
10% FBS and 10% dimethyl sulfoxide (DMSO). Cells were slowly
frozen at −80°C in an isopropanol bath overnight and stored long
term in the vapor phase of a liquid nitrogen freezer. The consent
process included conditions for sharing deidentified samples and
information with other investigators. No identifiable information will
be shared at any time per Health Insurance Portability and Accountability Act guidelines.

MATERIALS AND METHODS

Drugs and reagents
The following drugs were used in the course of this study: Cisplatin
(Sigma-Aldrich) was prepared as a 1-mM solution in saline per the
manufacturer’s instructions. MMC (Sigma-Aldrich) was prepared by
dissolving 0.5 mg/ml in water. HU (Sigma-Aldrich) was prepared
fresh in complete media prior to experiments per the manufacturer’s
instructions. The ATRi, VE-821 (Selleckchem) and Wee1i, MK-1775
(Selleckchem) were prepared as a 15 and 5 mM solutions in DMSO,
respectively. CldU and IdU were obtained from Sigma-Aldrich. ClickiT EdU Alexa Fluor 488 Imaging Kit was obtained from Invitrogen.
Concentration and duration of treatment are indicated in the corresponding figures and sections.

Cell culture and cell lines
U2OS, PEO1, HeLa, MCF7, HCT15, and A549 cell lines were grown
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) and penicillin and streptomycin
(100 U/ml each). U2OS cells with inducible OE of cyclin E (U2OS-CE)
were maintained in DMEM supplemented with 10% FBS (Invitrogen,
catalog no. 10500), penicillin-streptomycin-glutamine (Invitrogen,
catalog no. 10378-016), G418 (400 g/ml) (Invitrogen, catalog no.
10131-027), puromycin (1 g/ml) (Sigma-Aldrich, catalog no. P8833),
and tetracycline (2 g/ml) (Sigma-Aldrich, catalog no. T7660). Right
before the experiment, the cells were split into two aliquots. One aliquot
was cultured in media without tetracycline to induce cyclin E OE (OE
cells) and the other in media with doxycycline (1 g/ml) to maintain
low levels of ectopic cyclin E expression (NE cells). MOLT-4 and NCIH522 cell lines were grown in RPMI supplemented with 10% FBS
and penicillin and streptomycin (100 U/ml each). HMEC cell line was
grown in DMEM supplemented with 15% FBS and penicillin and streptomycin (100 U/ml each). FA-J cells (EUFA30-F) were immortalized
with human telomerase reverse transcriptase (hTERT) and cultured as
previously described (61). Stable FA-J pOZ–complemented cell lines
were generated and selected as previously described. U2OS and HeLa
FANCJ K/O CRISPR cell lines were generated as previously described
(24). Stable U2OS FANCJ K/O– and PEO1 pLenti–complemented
cell lines were generated by blasticidin selection (5 g/ml). Stable
HeLa and U2OS shRNA knockdown cell lines were generated by
puromycin selection (0.25 and 0.5 g/ml, respectively).
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Plasmid and shRNA constructs
The WT and S990A FANCJ pLentiviral vectors were a gift from
J. Chen. The WT and S990A pOZ vectors were generated as previously described. HeLa FANCJ K/O and U2OS cells were infected with
pLK0.1 vector containing shRNAs against nonsilencing control (NSC)
or one of three shRNAs against p21/CDKN1A (A) (target region:
3′UTR—CGCTCTACATCTTCTGCCTTA), (B) (CDS—GAGCGATGGAACTTCGACTTT), and (C) (CDS—GTCACTGTCTTGTACCCTTGT). pInducer20 empty vector and pInducer20 cyclin
E1 plasmids were obtained from Addgene. The FANCJ K/O U2OS
cells complemented with FANCJWT or FANCJS990A were further infected with the respected virus to express the empty vector or cyclin
E1 in a doxycycline inducible manner. shRNAs were obtained from
the UMMS shRNA core facility. The eGFP–pol- and eGFP-Rev1
constructs were used as described earlier (62, 63).

Immunoblotting and antibodies
Cells were harvested, lysed, and processed for Western blot analysis
as described previously using 150 mM NETN lysis buffer [20 mM
tris (pH 8.0), 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, 1 mM phenyl-
methyl-sulfonyl fluoride, leupeptin (10 mg/ml), and aprotinin
(10 mg/ml)]. For cell fractionation, we isolated cytoplasmic and soluble
nuclear fractions with the NE-PER Kit (Thermo Fisher Scientific)
according to the manufacturer’s protocol; to isolate the chromatin
fraction, the insoluble pellet was resuspended in radioimmuno
precipitation assay (RIPA) buffer and sonicated in a Bioruptor according
to the manufacturer’s protocol (medium power, 20 min, 30 s on, 30 s
off at 4°C). Proteins were separated using SDS–polyacrylamide gel
electrophoresis and electrotransferred to nitrocellulose membranes.
Membranes were blocked in 5% nonfat dry milk phosphate-buffered
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a failure to slow and reverse replication in response to stress is linked
to genomic instability and enhanced cell death (1). While gaps are
avoided by pausing replication in response to stress, reversed forks
are susceptible to nucleolytic processing. Fork degradation causes
genomic instability in BRCA-deficient cancer (34). Thus, we propose
that cancer cells avoid the vulnerability of reversed forks and replication gaps by favoring TLS polymerases.
In summary, our data reveal that TLS polymerases subvert the
replication stress response by restricting ssDNA gaps and that this
activity is targetable in cancer to reduce fitness. Our data also highlight the clinical importance of identifying TLS polymerase–dependent
cancers, especially those that lack current treatment options such as
ovarian that are sensitive to the TLSi in vitro. Leveraging this vulnerability by TLS inhibition alone or in conjunction with gap-inducing
therapies that include inhibitors of ATR, Wee1 and PARP as well as
cisplatin ideally will improve efficacy (20, 21). Conceivably, targeting TLS factors in cancer will also reduce the ability of the cancer to
mutate and, therefore, retain its vulnerability to other therapies. As
the TLSi restricts replication, gaps likely form due to a greater replication fork uncoupling (60). An important future goal will be to
identify biomarkers that signify TLS polymerase–dependent cancers.
A reasonable place to begin is with cancers expressing oncogenes
such as cyclin E, CDC25A, KRAS, MOS, and MYC. Identifying TLS
polymerase–dependent cancers will also be facilitated by uncovering
the core factors and modulators driving the TLS polymerase rewiring.
In addition to OE of TLS factors, TLS polymerases may also provide
mutational signatures or strong gene dependencies [i.e., cancer cell
line encyclopedia (CCLE)]. Collectively, our findings highlight the
importance of replication gaps as a cancer vulnerability in a wide
range of cancers.
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saline (PBS)/Tween and incubated with primary antibody (Ab) for
overnight at 4°C. Abs for Western blot analysis included anti–-
actin (Sigma-Aldrich), anti-FANCJ (E67), anti-vinculin (Sigma-Aldrich),
anti–cyclin E1 (Abcam), and anti-p21 (BD Pharmingen). Membranes
were washed and incubated with horseradish peroxidase–linked
secondary Abs (Amersham) for 1 hour at room temperature (RT)
and detected by chemiluminescence (Amersham).

Electron microscopy
For the EM analysis of replication intermediates, 5 × 106 to 10 × 106
U2OS FANCJ K/O CRISPR cells, transfected with either FANCJWT
or FANCJS990A, were harvested immediately after treatment with
HU at a 4 mM concentration for 2 hours. Genomic DNA was crosslinked by three rounds of incubation in 4,5′,8-trimethylpsoralen
(10 g/ml; Sigma-Aldrich) and 3 min of irradiation with 366-nm UV
light on a precooled metal block (64, 65). Cells were lysed and genomic DNA was isolated from the nuclei by proteinase K (Roche)
digestion and phenol-chloroform extraction. DNA was purified by
isopropanol precipitation, digested with PvuII HF in the proper buffer
for 3 to 5 hours at 37°C, and replication intermediates were enriched
on a benzoylated naphthoylated DEAE-cellulose (Sigma-Aldrich)
column. EM samples were prepared by spreading the DNA on carbon-
coated grids in the presence of benzyl-dimethyl-alkylammonium
chloride and visualized by platinum rotary shadowing. Images were
acquired on a transmission electron microscope (JEOL 1400 EX) with
side-mounted camera (AMTXR41 supported by AMT software v601)
and analyzed with ImageJ (National Institutes of Health). EM analysis
allows distinguishing duplex DNA—which is expected to appear as
DNA fiber assays
To directly visualize replication fork dynamics, we established single a 10-nm-thick fiber after the platinum/carbon coating step necessary
molecular DNA fiber analysis. In this assay, progressing replication for EM visualization—from ssDNA, which has a reduced thickness
forks in cells were labeled by sequential incorporation of two different of 5 to 7 nm. Internal ssDNA gaps behind forks are scored by meanucleotide analogs, IdU (50 M) and CldU (50 M), into nascent suring ssDNA regions located in the daughter arms of three-way
DNA strands for the indicated time and conditions. After nucleotide junction fork structures and excluding ssDNA discontinuities present
analogs were incorporated in vivo, the cells were collected, washed, at fork junctions. The criteria used for the unequivocal assignment
spotted (2.5 l of 105 cells/ml PBS cell suspension), and lysed on of reversed forks include the presence of a rhomboid structure at
positively charged microscope slides (Globe Scientific, #1358 W) by the junction itself to provide a clear indication that the junction is
7.5 l of spreading buffer [0.5% SDS, 200 mM tris-HCl (pH 7.4), and opened up and that the four-way junction structure is not simply
50 mM EDTA] for 8 min at RT. Individual DNA fibers were released the result of the occasional crossing of two DNA molecules (66). In
and spread by tilting the slides at a 45°. After air drying, the fibers addition, the length of the two arms corresponding to the newly
were fixed by 3:1 methanol:acetic acid at RT for 3 min. After air drying replicated duplex should be equal (b = c), whereas the length of the
again, fibers were rehydrated in PBS, denatured with 2.5 M HCl for parental arm and the regressed arm can vary (a ≠ b = c ≠ d). Con30 min, washed with PBS, and blocked with blocking buffer (3% BSA versely, canonical Holliday junction structures will be characterized
and 0.1%Trition in PBS) for 1 hour. Next, slides were incubated for by arms of equal length (a = b, c = d). EM analysis was performed by
2.5 hours with primary Abs (IdU: 1:100, mouse monoclonal anti- calculating the percentage of either reversed replication forks or inBrdU, Becton Dickinson 347580; CldU: 1:100, rat monoclonal anti- ternal ssDNA gaps in each sample.
BrdU, Abcam 6326) diluted in blocking buffer, washed several times
in PBS, and then incubated with secondary Abs (IdU: 1:200, goat anti- Viability assays
mouse, Alexa 488; CldU: 1:200, goat anti-rat, Alexa 594) in blocking Cells were seeded onto 96-well plates (500 cells per well, performed
buffer for 1 hour. After washing and air drying, the slides were in triplicates for each experiment) and incubated overnight. Next
mounted with Prolong (Invitrogen, P36930). Last, the visualization day, the cells were treated with increasing dose of MMC for 1 hour
of green and/or red signals by fluorescence microscopy (Axioplan 2 in serum-free media or cisplatin or TLSi and maintained in complete
imaging, Zeiss) will provide information about the active replication media for 5 days. Percent survival was measured using CellTitre-
directionality at the single molecular level.
Glo viability assay (Promega) photometrically in a microplate reader
(Beckman Coulter DTX 880 Multimode Detector).
S1 nuclease fiber assay
As described previously, cells were exposed to 50 M IdU to label Colony formation assay
replication forks, followed by 50 M CldU with 0.5 mM HU for 1 hour. For colony formation assays, either 500 or 1000 cells per well were
Subsequently, cells were permeabilized with CSK (cytoskeletal) buffer seeded into six-well plates and were treated continuously with or
Nayak et al., Sci. Adv. 2020; 6 : eaaz7808
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Immunofluorescence
Immunofluorescence was performed as described previously (33).
Cells were grown on coverslips in 10 M 5-bromo-2′-deoxyuridine
(BrdU) for 48 hours before the treatment with drugs. Cells were then
treated with the aforementioned drugs for 2 hours. After treatment,
cells were washed with PBS and preextracted with 0.5% Triton X-100
made in PBS on ice. Cells were then fixed using 4% formalin for
15 min at RT. Fixed cells were then incubated with primary Abs against
BrdU (Abcam) at 37°C for 1 hour. Cells were washed and incubated with
secondary Abs for 1 hour at RT. After washing, coverslips were mounted
onto glass slides using Vectashield mounting medium containing
4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories). For
EdU labeling, staining was carried out with Click-iT EdU imaging kit
(Invitrogen) according to the manufacturer’s instructions. For visualization of pol- and Rev1 foci, cells were transfected with either eGFP–
pol- or eGFP-Rev1, incubated for overnight, seeded on coverslips, and
again incubated for overnight and examined 4 hours after UV or 48 hours
after MMC. Cells were first permeabilized with 0.5% Triton X-100
made in PBS on ice and then fixed with 4% formalin and foci counted.

[100 mM NaCl, 10 mM MOPS (3-(N-morpholino) propanesulfonic
acid), 3 mM MgCl2 (pH 7.2), 300 mM sucrose, 0.5% Triton X-100] at
RT for 8 min, followed by S1 nuclease (20 U/ml) in S1 buffer [30 mM
sodium acetate (pH 4.6), 10 mM zinc acetate, 5% glycerol, and 50 mM
NaCl] for 30 min at 37°C. Last, cells were collected by scraping, pelleted,
and resuspended in 100 to 500 l of PBS; 2 l of cell suspension was
spotted on a positively charged slide and lysed and processed as described in the “DNA fiber assays” section.
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without different drugs as mentioned in the respective figures. Once
the colonies had developed, the cells were fixed with 90% methanol
and then stained with 0.05% (w/v) crystal violet solution. Plates were
then imaged using ChemiDoc Touch Imaging system (Bio-Rad), and
the number of colonies was counted using the Cell Profiler software
version 3.1.5 from Broad Institute.
Statistical methods
Statistical differences in DNA fiber assay, S1 nuclease assay, immuno
fluorescence, and colony forming assays were determined using a two-
tailed Mann-Whitney test. Statistical analysis was performed using
Excel and GraphPad Prism (version 7.0). In all cases, ns indicates
not significant (P > 0.01), **P < 0.01, *P < 0.001, and ****P < 0.0001.
SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/24/eaaz7808/DC1
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